Clin2
NCT06442423Possibly a fitRecruiting

Psilocybin study for people with psychiatric symptoms

TransdiagnosticDepression - Major Depressive DisorderAnxietyPTSD SymptomsPTSDSubstance UseSubstance Use Disorder (SUD)OCD

Treatments studied

Part of Mental health clinical trials.

This trial tests if psilocybin, a substance found in certain mushrooms, can help people with various mental health symptoms that affect daily life. You would take a single dose in a supervised setting and be monitored for changes in your mood and well-being.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
50 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You have at least one mental health symptom (like depression, anxiety, or others) that has caused problems in your daily life for the past 30 days.
  • You can speak and understand English well enough to give informed consent.
  • You must have a friend or family member who can drive you home after the dosing session, or agree to use study-provided transportation.
  • You need to have a regular doctor who can be contacted to confirm it is safe for you to participate.
  • You must be willing to avoid certain medications and substances before and during the study, and have stable psychological therapy or medications for at least a month before joining.
  • If you could become pregnant, you must agree to use effective birth control and have negative pregnancy tests.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07566104Not yet recruiting· Phase 2
Group therapy with psilocybin for depression

This study tests whether psilocybin—a psychedelic compound—combined with group therapy can help people with depression. Participants receive guided psilocybin sessions at UCLA and attend group therapy to process the experience.

Los Angeles, California
NCT07745569Not yet recruiting· Phase 2
Psychedelic therapy study for depression or PTSD

This study tests whether electromagnetic brain stimulation and a psychedelic drug called psilocybin can help people with depression or PTSD. It aims to see how these treatments affect mood and behavior, and whether they are safe and helpful.

NCT06247839Recruiting· Phase 3
Psilocybin for depression: changing self-focus

This trial tests whether a single dose of psilocybin can help people with treatment-resistant depression by changing how they focus on themselves. It aims to understand how psilocybin affects brain activity and self-related thinking.

Charlestown, Massachusetts
NCT06072898Recruiting· Phase 2
Psilocybin brain imaging trial for depression

This study tests whether a single dose of psilocybin (a psychedelic compound) can help treat depression by looking at brain changes on MRI. It is designed for people with moderate-to-severe depression who have not responded well to other treatments.

Toronto, Ontario
NCT07703722Recruiting· Phase 3
Psilocybin and therapy for depression with trauma

This trial tests psilocybin (a compound from certain mushrooms) combined with a structured therapy to see if it helps people with depression linked to trauma. It focuses on how the treatment affects the connection between the gut and brain.

Islamabad, Capital
NCT07183748Recruiting· Phase 2
Psilocybin microdosing plus therapy for hard-to-treat depression

This trial tests whether taking very small, repeated doses of psilocybin (a substance found in magic mushrooms) along with talk therapy can help people with depression that hasn't gotten better with other treatments. You'll need to stop your current depression medications and avoid drugs or alcohol for the study period.

Beersheba

Hear when a new Transdiagnostic trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.